Quantifying cortical atrophy.

Journal of Neurology Neurosurgery & Psychiatry (Impact Factor: 4.92). 01/1985; 47(12):1314-8. DOI: 10.1136/jnnp.47.12.1314
Source: PubMed

ABSTRACT Most of the methods of quantifying cortical atrophy that have been proposed involve the estimation of the volume of enlarged sulci in the cerebral cortex. The authors propose that the surface area of the sulci is a more valid measure of cortical atrophy, and describe a system for measuring the surface area of the cortex, and present data in support of the method's reliability and validity.

  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: Utilizing volumetric measures of brain morphology, the relationship between cortical atrophy and ventricular dilation was examined in a sample of 59 Alzheimer's Disease patients and 48 closed head injury patients. Correlation matrices were constructed and factor analyses performed in order to elucidate the various relationships. In the Alzheimer Disease sample there appeared to be a moderately strong relationship between cortical atrophy and ventricular volume. However, analyses also lent support to the position that cortical atrophy and ventricular dilation reflect processes which are related yet somewhat independent. Results obtained from the closed head injury sample indicated that focal damage effects were more evident in cortical atrophy measures, while generalized effects were relatively more important in ventricular dilation. Finally, the relationships between neuropsychological performance and various combinations of high and low cortical atrophy and ventricular volume measures were modest.
    International Journal of Neuroscience 09/1986; 30(1-2):87-99. · 1.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The modifications in the CSF content of glutamate and GABA in patients afflicted with primary degenerative dementia (PDD) and olivo-ponto-cerebellar atrophy (OPCA) have been evaluated. Control subjects (with disk herniation) were also included in the study. The amino-acids assays were carried out utilizing enzymatic-bioluminescence technique. GABA levels in controls were 803 +/- 98 (n = 7) and in demented patients 702 +/- 98 (n = 7) pmol/ml. Glutamate levels were 2067 +/- 244 (n = 10) in controls, 1190 +/- 81 (n = 16) pmol/ml (vs controls p less than 0.01) in demented patients, and 1116 +/- 146 (vs controls p less than 0.01) in OPCA patients. These results suggest that CSF glutamate levels in severely demented patients might be a result of generalized neuronal loss in the brain with a reactive gliosis.
    Acta Neurologica Scandinavica 07/1992; 85(6):430-5. · 2.47 Impact Factor

Full-text (2 Sources)

Available from
Oct 14, 2014